Compare Lamb Weston Holdings Inc (LW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lamb Weston Holdings Inc trades at $52.79 (market cap $7.12B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.7× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| LW | VRTX | |
|---|---|---|
Market Cap | $7.12B | $132.79B |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $529.65 |
52-Week Low | $38.48 | $376.62 |
Enterprise Value | $11.00B | $126.92B |
Dividend Yield | 2.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $52.27, up 0.42% today, with a bullish technical outlook and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and trades at a P/E of 25.13. Recent Q2 2026 results exceeded expectations with EPS of $0.87 versus $0.626 estimated. The company maintains a solid dividend yield with a recent $0.38 per share payout announced.
The outlook is positive given operational improvements and cost savings, though international headwinds and margin pressures pose risks. Analyst consensus is a 'Hold' with a $53.86 price target, indicating modest upside. Investors should weigh strong North American growth against geopolitical and cost challenges impacting international segments.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
